A Duttaroy, P Kanakaraj, BL Osborn, H … - Diabetes, 2005 - Am Diabetes Assoc The primary therapeutic goal for the treatment of diabetes is maintenance of a
long-term, near-normoglycemic condition and prevention of the onset or
progression of the complications associated with the disease. Although ... Cited by 27 - Related articles - All 8 versions
BL Osborn, L Sekut, M Corcoran, C Poortman, … - European journal of pharmacology, 2002 - Elsevier Growth hormone (GH) replacement therapy is used to treat GH deficiency.
Treatment requires daily administration because of the short plasma t 1/2 of GH.
Albutropin, human GH fused at its N-terminus with human serum albumin, ... Cited by 46 - Related articles - All 4 versions
W Halpern, TA Riccobene, H Agostini, K Baker … - Pharmaceutical research, 2002 - Springer Received July 10, 2002; accepted July 19, 2002. Purpose. AlbugraninTM fusion
protein is recombinant granulocyte colony stimulating factor (rG-CSF)
genetically fused at its N- terminus to the C-terminus of recombinant serum ... Cited by 26 - Related articles - BL Direct - All 4 versions
[CITATION] Mealtime treatment with insulin analog improves postprandial hiperglycemia in patients with …
RJ Melder, BL Osborn, T Riccobene, P … - Cancer Immunology, Immunotherapy, 2005 - Springer Abstract Purpose: Albuleukin fusion protein is a re- combinant human
interleukin-2 (rIL-2) genetically fused to recombinant human serum albumin
(rHSA). The pharmacokinetics and pharmacologic activity of Albu- leukin ... Cited by 28 - Related articles - All 3 versions
[CITATION] Improve insulin binding to monocytes of IDDM patients intensively treatment with lys (B28) …
C Girish, S Manikandan, M Jayanthi - Indian Journal of Medical Sciences, 2006 - Medknow Diabetes is a metabolic disease with high prevalence worldwide. Exogenous
insulin is used in the management of this condition. The development of human
insulin has provided tighter control of glycaemia in diabetic patients. ... Cited by 8 - Related articles - Cached - All 6 versions
I Rakatzi, S Ramrath, D Ledwig, O Dransfeld, T … - Diabetes, 2003 - ncbi.nlm.nih.gov The potentially enhanced mitogenic activity of insulin analogs represents a
safety risk that requires detailed analysis of new analogs considered for
therapeutic applications. We assessed the signaling properties and ... Cited by 46 - Related articles - BL Direct - All 2 versions
